cyc 202 has been researched along with nu 6140 in 1 studies
| Studies (cyc 202) | Trials (cyc 202) | Recent Studies (post-2010) (cyc 202) | Studies (nu 6140) | Trials (nu 6140) | Recent Studies (post-2010) (nu 6140) |
|---|---|---|---|---|---|
| 979 | 7 | 393 | 12 | 0 | 11 |
| Protein | Taxonomy | cyc 202 (IC50) | nu 6140 (IC50) |
|---|---|---|---|
| Aurora kinase A | Homo sapiens (human) | 0.067 | |
| Cyclin-T1 | Homo sapiens (human) | 5.1 | |
| Cyclin-dependent kinase 1 | Homo sapiens (human) | 5.8 | |
| Cyclin-dependent kinase 4 | Homo sapiens (human) | 0.94 | |
| G2/mitotic-specific cyclin-B1 | Homo sapiens (human) | 5.8 | |
| Interferon-induced, double-stranded RNA-activated protein kinase | Homo sapiens (human) | 2 | |
| G1/S-specific cyclin-D1 | Homo sapiens (human) | 0.94 | |
| G1/S-specific cyclin-E1 | Homo sapiens (human) | 1.1 | |
| Cyclin-dependent kinase 2 | Homo sapiens (human) | 0.75 | |
| Cyclin-dependent kinase 7 | Homo sapiens (human) | 2.3 | |
| Cyclin-dependent kinase 9 | Homo sapiens (human) | 5.1 | |
| Cyclin-H | Homo sapiens (human) | 2.3 | |
| CDK-activating kinase assembly factor MAT1 | Homo sapiens (human) | 2.3 | |
| Cyclin-dependent-like kinase 5 | Homo sapiens (human) | 8.8 | |
| Cyclin-dependent kinase 5 activator 1 | Homo sapiens (human) | 8.8 | |
| Aurora kinase B | Homo sapiens (human) | 0.035 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, X; Christ, J; Eisenbrand, G; Merz, KH; Muehlbeyer, S; Thommet, A; Vatter, S; Wölfl, S; Zeller, J | 1 |
1 other study(ies) available for cyc 202 and nu 6140
| Article | Year |
|---|---|
Identification of a Water-Soluble Indirubin Derivative as Potent Inhibitor of Insulin-like Growth Factor 1 Receptor through Structural Modification of the Parent Natural Molecule.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Chemistry Techniques, Synthetic; Drug Screening Assays, Antitumor; Humans; Indoles; Oximes; Protein Kinase Inhibitors; Receptor, IGF Type 1; Signal Transduction; Solubility; Structure-Activity Relationship | 2017 |